US89377M1099
US89377M1099
TransMedics Group, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.69B EUR | 2.3B EUR | 3.43B EUR | 4.17B EUR |
Enterprise Value | 3.13B EUR | 2.7B EUR | 3.84B EUR | 4.2B EUR |
Valuation Multiples | ||||
Trailing P/E | 20.17x | 15.16x | 19.98x | 25.32x |
Forward P/E | 34.55x | -- | -- | -- |
Price to Sales | 4.03x | 3.44x | 5.4x | 9.02x |
Price to Book | 5.21x | 4.44x | 6.95x | 8.81x |
EV/Revenue | 4.69x | 4.03x | 6.03x | 9.09x |
EV/EBITDA | 27.11x | 20.7x | 27.59x | 37.66x |
Price to FCF (P/FCF) | 60.48x | 29.1x | 22.69x | 25.5x |
EV/FCF | 70.44x | 34.1x | 25.34x | 25.69x |
FCF Yield | 1.65% | 3.44% | 4.41% | 3.92% |